List of Excipients in Branded Drug KEEPS MINOXIDIL TOPICAL

« Back to Dashboard

Generic Drugs Containing KEEPS MINOXIDIL TOPICAL

Company	Ingredient	NDC	Excipient
THIRTY MADISON INC	minoxidil	71713-092	ALCOHOL
THIRTY MADISON INC	minoxidil	71713-092	BUTANE
THIRTY MADISON INC	minoxidil	71713-092	BUTYLATED HYDROXYTOLUENE
THIRTY MADISON INC	minoxidil	71713-092	CETYL ALCOHOL

What are the Most Frequently-Used Excipients in KEEPS MINOXIDIL TOPICAL?

# Of NDCs	Excipient
2	ALCOHOL
2	BUTANE
2	BUTYLATED HYDROXYTOLUENE
2	CETYL ALCOHOL

KEEPS Minoxidil Topical: Excipient Strategy, Regulatory Position, and Commercial Opportunities

Last updated: October 7, 2026

KEEPS Minoxidil Topical is an OTC hair-regrowth product whose commercial differentiation depends more on formulation tolerability, delivery format, packaging, subscription economics, and brand control than on active-ingredient exclusivity. Minoxidil is a mature molecule with limited composition-of-matter protection remaining. The strongest opportunities are foam and low-residue systems, scalp-compatible excipient selection, proprietary packaging, combination regimens, and consumer adherence programs.

What is KEEPS Minoxidil Topical?

KEEPS markets topical minoxidil products for androgenetic alopecia, including 5% foam and liquid formats. The active ingredient is minoxidil, generally at a 5% concentration for adult male hair regrowth products. FDA labeling directs users to apply the product to the scalp according to the dosage instructions and warns against use in certain populations, including individuals with scalp disease or those experiencing sudden or patchy hair loss.[1]

The product family is commercially positioned around direct-to-consumer access, recurring purchases, telehealth interaction, and hair-loss treatment programs. The core commercial constraint is that minoxidil itself is widely available through retail, online pharmacies, private-label manufacturers, and generic OTC channels.

Product formats and likely excipient profiles

The principal KEEPS-relevant dosage forms are:

Format	Typical minoxidil strength	Common excipient architecture	Commercial rationale
Foam aerosol	5%	Alcohol, water, glycerin, fatty alcohols, surfactant, acids, hydrocarbon propellant	Fast drying, lower visible residue, improved cosmetic acceptability
Topical solution	5%	Alcohol, propylene glycol, purified water	Low manufacturing cost and simple liquid delivery
Lower-strength solution	2% in some markets or legacy products	Alcohol, propylene glycol, water	Potentially improved tolerability, lower efficacy perception
Dropper or metered liquid	Usually 5%	Solvent system with humectant and viscosity control	Dosing precision and lower packaging cost

Public OTC labeling for 5% minoxidil foam commonly identifies ethanol, glycerin, cetyl alcohol, stearyl alcohol, polysorbate 60, citric acid, lactic acid, purified water, and a hydrocarbon propellant among inactive ingredients.[1] Liquid minoxidil products commonly use ethanol, propylene glycol, and purified water.[2]

The exact commercial formulation and manufacturing source should be established from the current package label, FDA listing, and supplier documentation before making a regulatory or patent conclusion.

What excipients are most important in KEEPS Minoxidil Topical?

The excipient strategy determines application feel, scalp irritation, drying time, residue, odor, stability, and repeat-use adherence.

Ethanol

Ethanol is a principal solvent in liquid and foam minoxidil products. It supports minoxidil solubilization, rapid evaporation, and a dry application profile. Its disadvantages include burning, dryness, barrier disruption, and increased irritation on inflamed or compromised scalp skin.

Commercial optimization opportunities include:

• Lowering ethanol concentration while maintaining minoxidil solubility.
• Using co-solvents to reduce solvent harshness.
• Controlling evaporation rate to limit cooling and stinging.
• Reducing odor through solvent selection and packaging.
• Matching solvent strength to the intended use site and consumer segment.

A lower-ethanol product could appeal to users who discontinue treatment because of burning or dryness. Any change must be assessed for minoxidil precipitation, dose uniformity, microbial control, and long-term stability.

Propylene glycol

Propylene glycol is widely used in minoxidil solutions as a solvent and humectant. It can support solubility and skin deposition, but it is also associated with irritation and allergic contact dermatitis in some users. A propylene-glycol-free formulation is one of the clearest commercial opportunities in topical minoxidil.

Potential alternatives include:

• Glycerin.
• Propanediol.
• Pentylene glycol.
• Polyethylene glycol systems.
• Transcutol-type solvents, subject to regulatory and toxicological review.
• Solubilizer combinations that reduce reliance on any single solvent.

A replacement is commercially valuable only if it maintains minoxidil concentration, clarity, delivery, preservative performance, and acceptable scalp feel. A “propylene glycol-free” claim could support premium pricing, but the claim requires substantiation and compliant labeling.

Glycerin and other humectants

Glycerin can reduce the dry feel associated with ethanol and support scalp moisturization. Excessive humectant loading can create tackiness, slow drying, or increase hair clumping. The optimal level depends on whether the product is a foam, spray, dropper solution, or leave-on scalp serum.

Propanediol and other multifunctional glycols may provide a different balance among humectancy, solvent capacity, skin feel, and preservative support. These systems can be useful in a premium liquid or pump spray, especially where the brand seeks to avoid the heavy, oily, or sticky profile associated with some traditional solutions.

Cetyl alcohol and stearyl alcohol

Fatty alcohols are functional components of many minoxidil foams. They contribute to foam structure, emulsion stability, texture, and after-feel. They are not equivalent to volatile alcohols such as ethanol and are generally used to improve product body and spreadability.

Their commercial value is primarily sensory:

• Creamier foam.
• Better scalp spread.
• Lower run-off.
• Reduced visible wetness.
• More controlled application to thinning areas.

The main formulation risks are waxy residue, hair drag, collapse of foam structure, and inconsistent dispensing at different temperatures.

Polysorbate 60 and related surfactants

Polysorbate 60 can support emulsion and foam stability. Surfactant selection affects foam collapse, rinsability, scalp compatibility, and the potential for irritation. A differentiated product could use a milder surfactant system, but the change would require reformulation work and stability testing.

Surfactant reduction is not automatically beneficial. A low-surfactant system may have poorer uniformity, reduced foam quality, or increased phase separation.

Acids and pH control

Citric acid and lactic acid may be used for pH adjustment and formulation control. pH affects scalp tolerability, preservative performance, solubility, viscosity, and chemical stability.

A commercial development program should establish:

• Target pH range.
• Minoxidil solubility at the selected pH.
• Skin irritation profile.
• Compatibility with the container closure.
• Stability under accelerated and real-time conditions.
• Effect on odor and color.

The claim “pH-balanced” has limited value unless the product delivers a measurable sensory or tolerability advantage.

Propellants

Foam products generally use hydrocarbon propellants. Propellant selection affects can pressure, foam density, discharge rate, residual product, flammability classification, and package compatibility.

Opportunities include:

• Lower-residue foam.
• More stable discharge across temperature ranges.
• Metered dispensing.
• Reduced can waste.
• Improved control for users with long hair or localized thinning.
• Packaging that limits propellant loss after partial use.

Propellant and package changes can create meaningful product differentiation but also introduce transport, flammability, pressure, and manufacturing requirements.

What excipient strategy offers the strongest commercial opportunity?

The strongest near-term opportunity is a tolerability-led, propylene-glycol-free liquid or foam with improved cosmetic performance.

Strategy	Consumer benefit	Technical difficulty	Commercial potential
Propylene-glycol-free solution	Lower irritation risk for some users	Medium	High
Lower-odor ethanol system	Better daily acceptability	Medium	Medium-high
Fast-drying foam	Less residue and styling disruption	Medium	High
Moisturizing foam	Reduced dryness	Medium	Medium
Metered pump or spray	More consistent dosing	Medium	High
Preservative-minimized system	Appeal to sensitive-skin users	High	Medium
Liposomal or nanoparticle delivery	Premium positioning and potential deposition benefits	High	Uncertain
Combination scalp serum	Cross-selling and regimen expansion	Medium	High
Water-based liquid	Improved sensory profile	High	Medium-high

Formulation concepts

A practical development pipeline could include four tiers.

Tier 1: Low-risk reformulation

A conventional 5% solution could be optimized through:

• Propylene glycol replacement or reduction.
• Ethanol adjustment.
• Glycerin or propanediol balancing.
• Improved odor control.
• Better dropper or pump dosing.

This approach has the shortest development timeline because it preserves the established active ingredient and route of administration.

Tier 2: Premium foam

A premium foam could target:

• Rapid drying.
• Low residue.
• Reduced scalp sting.
• Improved application to receding hairlines.
• Stable discharge at room temperature.
• Better performance under bathroom storage conditions.

The value proposition is adherence rather than increased pharmacologic potency.

Tier 3: Sensitive-scalp product

A sensitive-scalp formulation could reduce or eliminate propylene glycol, lower volatile solvent exposure, and use a simplified excipient list. The product could be marketed around reduced dryness or improved comfort, subject to substantiation and compliant OTC claims.

Tier 4: Delivery-system innovation

Liposomal, microemulsion, nanoemulsion, or film-forming systems may support premium pricing and intellectual-property creation. These systems face higher technical risk because they must demonstrate reproducible minoxidil loading, scalp deposition, stability, scale-up, and acceptable safety.

A delivery system that increases systemic exposure could create a regulatory problem rather than a commercial advantage. The target should be consistent topical delivery with controlled residue, not simply greater penetration.

What FDA regulatory status applies to KEEPS Minoxidil Topical?

Topical minoxidil hair-regrowth products are regulated as OTC drug products under the FDA’s nonprescription drug framework. FDA regulations identify minoxidil as an active ingredient for hair-growth products when used at permitted concentrations and with required labeling conditions.[3]

Key regulatory considerations include:

Issue	Relevance
Active ingredient	Minoxidil
Common OTC strength	5%
Dosage form	Foam, solution, or other topical format
Regulatory route	OTC monograph framework or applicable approved product pathway
Labeling	Drug Facts, warnings, directions, use restrictions
Manufacturing	Current good manufacturing practice requirements
Claims	Hair regrowth claims must remain within permitted OTC labeling
New excipients	May require safety justification or additional FDA review
Combination products	May require a different regulatory analysis

A material change in excipients, dosage form, delivery technology, or labeling can affect whether the product remains within the applicable OTC monograph conditions. A new delivery system may require a formal FDA submission if it changes the product’s regulatory characteristics or falls outside the monograph framework.

What is the Orange Book and patent status of KEEPS Minoxidil Topical?

KEEPS Minoxidil Topical is unlikely to have meaningful Orange Book exclusivity comparable to a newly approved prescription drug. OTC monograph products generally do not depend on Orange Book-listed patents for market protection in the same way as approved prescription products.

Minoxidil’s original composition-of-matter patents are long expired. The active ingredient is available from multiple suppliers, and competing 2% and 5% topical products are widely marketed.

Patent protection that may still matter

Potentially relevant protection may attach to:

• Foam composition.
• Propellant system.
• Container and valve assembly.
• Metered-dose dispensing.
• Encapsulation or particle engineering.
• Combination treatment.
• Scalp-delivery technology.
• Manufacturing process.
• Stability-enhancing excipient system.
• Digital adherence or dispensing integration.

These rights would be narrower than a basic minoxidil patent. Their commercial value depends on claim scope, ownership, enforceability, freedom-to-operate analysis, and whether competing products can design around them.

Protection category	Likely strength for a KEEPS-type product
Minoxidil molecule	Weak or expired
Conventional 5% solution	Weak
Standard ethanol/propylene glycol vehicle	Weak
Propylene-glycol-free composition	Potentially moderate if claims are specific and non-obvious
Proprietary foam system	Moderate, depending on claim drafting
Metered dispensing system	Moderate
Novel delivery platform	Potentially strong but expensive to defend
Brand and customer relationship	Often more commercially important than formulation patents

When does KEEPS Minoxidil lose exclusivity?

KEEPS does not appear to rely on a conventional prescription-drug exclusivity period for topical minoxidil. The product competes in an established OTC market where generic and private-label products can enter without waiting for the expiration of a KEEPS-specific active-ingredient patent.

Market exclusivity can still arise from:

• Trademark rights in the KEEPS brand.
• Confidential manufacturing arrangements.
• Supplier agreements.
• Proprietary packaging.
• Trade secrets.
• Formulation patents.
• Product-specific data or regulatory approvals.
• Subscription retention and customer acquisition economics.

This is commercial exclusivity rather than molecule-based regulatory exclusivity. Competitors can generally sell minoxidil products while avoiding KEEPS trademarks, protected packaging, and any enforceable formulation or delivery claims.

Are Paragraph IV challenges relevant to KEEPS Minoxidil?

Paragraph IV litigation is primarily associated with abbreviated new drug applications for approved prescription or FDA-listed drug products. It is not the normal competitive mechanism for a standard OTC monograph minoxidil product.

A competitor seeking to launch a competing topical minoxidil product would more likely rely on:

• OTC monograph compliance.
• A separate FDA pathway.
• Private-label manufacturing.
• Trademark clearance.
• Patent clearance for any formulation or device claims.
• Consumer and retail channel competition.

A Paragraph IV event would become more relevant only if a specific KEEPS product were supported by an FDA-approved application with Orange Book-listed patents.

What formulation patents could protect a KEEPS product?

The most defensible formulation claims would focus on specific combinations and measurable technical results rather than broad claims to “minoxidil in a topical vehicle.”

Potential claim themes include:

1. A 5% minoxidil composition without propylene glycol.
2. A defined ethanol and polyol ratio that maintains clarity and stability.
3. A foam with specified density, collapse time, and discharge characteristics.
4. A metered-dose package delivering a defined minoxidil mass per actuation.
5. A formulation with controlled deposition and reduced residue.
6. A preservative system that maintains microbial quality with lower irritation.
7. A stabilized minoxidil composition with defined impurity limits.
8. A combination of minoxidil and a second active under a specific dosing regimen.

Patent strength would improve if the claims were supported by comparative data showing unexpected advantages, such as lower irritation, improved stability, superior deposition, or more consistent dosing.

A patent directed only to routine substitution of one common solvent for another may face obviousness challenges. The strongest applications should include broad and narrow claims, formulation examples, process parameters, package compatibility data, and comparative performance results.

What manufacturing and intellectual-property barriers exist?

The active ingredient is not the primary manufacturing barrier. The more important barriers are process consistency, filling and packaging, and quality control.

Manufacturing issues

Foam products require control of:

• Concentrate preparation.
• Propellant charging.
• Can and valve compatibility.
• Fill weight.
• Pressure.
• Foam density.
• Discharge rate.
• Temperature sensitivity.
• Residual product.
• Flammability controls.

Liquid products require control of:

• Minoxidil dissolution.
• Crystallization risk.
• Solvent evaporation.
• Dropper calibration.
• Fill uniformity.
• Container compatibility.
• Microbial quality.
• Long-term color and odor stability.

Supply-chain issues

Commercial risk can arise from:

• Dependence on a single minoxidil API supplier.
• Limited availability of pharmaceutical-grade excipients.
• Propellant sourcing constraints.
• Aerosol-can capacity.
• Contract manufacturing concentration.
• Packaging component shortages.
• Shipping restrictions for flammable aerosols.

A formulation with standard solvents has lower supply risk than one dependent on a specialized lipid, polymer, or delivery platform.

Which companies challenge KEEPS Minoxidil commercially?

KEEPS competes with branded, generic, retail, pharmacy, and telehealth products. The principal competitive groups include:

• Rogaine and other legacy minoxidil brands.
• Store-brand 5% minoxidil products.
• Online pharmacy and marketplace sellers.
• Telehealth hair-loss companies.
• Compounded topical providers.
• Prescription hair-loss programs using finasteride, dutasteride, or combination therapy.
• Cosmetic scalp-serum brands.

The primary competitive advantages are price, recurring delivery, medical credibility, convenience, application experience, and adherence support. The product with the lowest unit cost does not necessarily win if consumers perceive it as messy, irritating, or difficult to use consistently.

How does KEEPS compare with other topical minoxidil products?

Attribute	KEEPS-style branded product	Generic liquid	Legacy branded foam	Premium delivery system
Active ingredient	Minoxidil	Minoxidil	Minoxidil	Minoxidil
Typical strength	5%	2% or 5%	5%	Usually 5%
Main differentiator	Telehealth and subscription	Price	Cosmetic usability	Delivery and premium claims
Excipient opportunity	High	Limited	Moderate	High
Patent position	Product-specific, if any	Usually limited	Device or formulation-specific	Potentially stronger
Consumer risk	Subscription price and adherence	Irritation or residue	Cost	Safety, regulatory, and evidence burden
Gross-margin opportunity	Brand and recurring purchase	Low to moderate	Moderate	Potentially high

What commercial opportunities exist beyond the core product?

The largest opportunities are product-system opportunities rather than a single improved bottle.

Subscription and adherence

Minoxidil requires sustained use. KEEPS can monetize:

• Automatic replenishment.
• Application reminders.
• Treatment-progress tracking.
• Refill timing based on expected consumption.
• Bundled scalp-care products.
• Clinician review.
• Cross-selling of prescription hair-loss products.

A formulation that improves comfort can reduce discontinuation and increase customer lifetime value.

Sensitive-scalp segmentation

A propylene-glycol-free, reduced-odor, low-residue product could target consumers who have stopped using conventional solutions. This segment supports premium pricing if the product demonstrates better comfort without compromising dosing or stability.

Foam and travel formats

Small-format, leak-resistant, or metered products can address travel, gym, and workplace use. A package that delivers a reproducible dose while minimizing mess may have stronger commercial value than a novel excipient with no visible consumer benefit.

Combination regimens

A KEEPS regimen could pair minoxidil with non-drug scalp-care products, such as:

• Gentle shampoo.
• Anti-dandruff shampoo.
• Scalp moisturizer.
• Sun-protection product for exposed scalp.
• Cosmetic hair-fiber products.

Combination claims involving additional drugs require careful regulatory review. Cosmetic and drug positioning must remain distinct.

Geographic expansion

The opportunity varies by jurisdiction. A U.S. OTC monograph strategy may not translate directly to the European Union, United Kingdom, Canada, Australia, or Asian markets. Each market can impose different requirements for:

• OTC or prescription classification.
• Permitted minoxidil concentration.
• Warning language.
• Cosmetic claims.
• Import and manufacturing licenses.
• Pharmacovigilance.
• Packaging and language.
• Aerosol transport.

A non-aerosol foam or pump product may simplify some distribution issues in markets where aerosol shipment is expensive or restricted.

Key Takeaways

• KEEPS Minoxidil Topical competes in a mature OTC market with limited active-ingredient exclusivity.
• The strongest excipient opportunity is a better-tolerated, propylene-glycol-free or lower-solvent formulation.
• Foam, metered dispensing, low residue, and improved odor are commercially meaningful differentiation points.
• Conventional minoxidil solutions have weak patent barriers; formulation, delivery, packaging, and process patents offer the main potential protection.
• Paragraph IV litigation is generally not the central competitive risk for a standard OTC monograph product.
• Manufacturing complexity is higher for aerosol foam than for liquid solution, particularly around propellant, valve, pressure, and fill controls.
• KEEPS’s strongest commercial assets are likely brand, telehealth distribution, subscription retention, and adherence support.
• A premium formulation requires comparative evidence on tolerability, stability, dosing, and consumer use experience.

FAQs About KEEPS Minoxidil Topical

Is KEEPS Minoxidil Topical a generic drug?

It is a branded OTC minoxidil product, but it competes with generic and store-brand minoxidil products containing the same active ingredient.

Does KEEPS Minoxidil contain propylene glycol?

Liquid minoxidil products commonly contain propylene glycol. Foam products often use a different excipient system. The current package Drug Facts label controls the formulation-specific answer.

Can a propylene-glycol-free minoxidil product receive patent protection?

Yes, but a patent would need claims directed to a specific composition, concentration range, process, or demonstrated technical advantage. Simple substitution of a known solvent may face obviousness objections.

Is minoxidil foam better than minoxidil solution?

Foam often has advantages in drying time, residue, and cosmetic acceptability. Solution may have lower manufacturing cost and easier dose-volume control. Clinical and commercial value depends on consistent use and tolerability.

Can KEEPS add finasteride to topical minoxidil?

A minoxidil-finasteride combination may require a different regulatory pathway, evidence package, labeling analysis, and safety assessment than an OTC minoxidil product. It should not be treated as a routine excipient modification.

References

1. DailyMed. (n.d.). Minoxidil topical aerosol, 5%: Drug Facts and labeling information. U.S. National Library of Medicine.
2. DailyMed. (n.d.). Minoxidil topical solution, 5%: Drug Facts and labeling information. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2023). 21 C.F.R. Part 341: Active ingredients for over-the-counter human use in external analgesic and hair growth drug products.
4. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.